Female Health Company names chief commercial officer

MIAMI — The Female Health Company/Veru Healthcare on Thursday named Brian Groch the company's chief commercial officer. He will report to Mitchell Steiner, president and CEO of The Female Health Company/Veru Healthcare.



“Brian brings an extensive commercial background, having served in senior leadership positions for some of the best known and highly regarded companies in our industry,” stated Steiner. “He has deep experience across multiple therapeutic areas, such as oncology, urology, neurology and cardiology, among others, and an outstanding record of success developing and executing global marketing strategies, generating brand awareness and launching new products." 



Groch will be responsible for all sales and marketing activities, with the goal of coordinating prelaunch, launch and sales and marketing activities. He will develop, implement and manage the prescription products infrastructure for the overall commercial organization, including reimbursement, market access, payer policies, sales and marketing, inventory and distribution, trade and customer service.



The initial focus for his team will be to establish the FC2 prescription business infrastructure to produce new and immediate revenue in the U.S., to coordinate the prelaunch and launch activities for Tamsulosin DRS (Tamsulosin HCl extended release for oral suspension) for the treatment of benign prostatic hyperplasia and manage the marketing and sales activities for PreBoost, FHC's recently launched proprietary over the counter product for the management of premature ejaculation.  



Groch has more than 30 years of experience in the pharmaceutical and biotechnology industries specializing in lobbying health policy change, global sales leadership, marketing, trade and distribution, contract negotiations, presentations and client/patient relations. He most recently served as chief commercial officer of Telesta Therapeutics overseeing the global commercial strategy for the first new biologic for bladder cancer. 



Groch began his career at Merck, where he rose through the sales and marketing ranks from 1988 to 2002. He later became head of market access for Dendreon, a biotech company that developed and launched Provenge for metastatic prostate cancer in 2010. In 2013, he was appointed VP market access for Horizon Therapeutics, where he played a key role in building the company’s orphan commercial business capabilities.



Groch earned a Master of Science degree in Healthcare Administration and Marketing and a Bachelor of Science degree in Physiology from Central Michigan University.